Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy
Article first published online: 21 AUG 2002
Copyright © 2002 Wiley-Liss, Inc.
International Journal of Cancer
Volume 101, Issue 6, pages 555–559, 20 October 2002
How to Cite
Møller, P., Borg, Å., Evans, D. G., Haites, N., Reis, M. M., Vasen, H., Anderson, E., Steel, C. M., Apold, J., Goudie, D., Howell, A., Lalloo, F., Mæhle, L., Gregory, H. and Heimdal, K. (2002), Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int. J. Cancer, 101: 555–559. doi: 10.1002/ijc.10641
- Issue published online: 17 SEP 2002
- Article first published online: 21 AUG 2002
- Manuscript Accepted: 21 JUN 2002
- Manuscript Revised: 11 JUN 2002
- Manuscript Received: 19 MAR 2002
- breast cancer;
Dedicated clinics have been established for the early diagnosis and treatment of women at risk for inherited breast cancer, but the effects of such interventions are currently unproven. This second report on prospectively diagnosed inherited breast cancer from the European collaborating centres supports the previous conclusions and adds information on genetic heterogeneity and the effect of oophorectomy. Of 249 patients, 20% had carcinoma in situ (CIS), 54% had infiltrating cancer without spread (CaN0) and 26% had cancer with spread (CaN+). Five-year survival was 100% for CIS, 94% for CaN0 and 72% for CaN+ (p = 0.007). Thirty-six patients had BRCA1 mutations, and 8 had BRCA2 mutations. Presence of BRCA1 mutation was associated with infiltrating cancer, high grade and lack of oestrogen receptor (p < 0.05 for all 3 characteristics). For BRCA1 mutation carriers, 5-year survival was 63% vs. 91% for noncarriers (p = 0.04). For CaN0 patients, mutation carriers had 75% 5-year disease-free survival vs. 96% for noncarriers (p = 0.01). Twenty-one of the mutation carriers had undergone prophylactic oophorectomy, prior to or within 6 months of diagnosis in 13 cases. All but 1 relapse occurred in the 15 who had kept their ovaries, (p < 0.01); no relapse occurred in those who had removed the ovaries within 6 months (p = 0.04) Contralateral cancer was more frequently observed in mutation noncarriers, but this finding did not reach statistical significance. Our findings support the concept that BRCA1 cancer is biologically different from other inherited breast cancers. While current screening protocols appear satisfactory for the majority of women at risk of familial breast cancer, this may not be the case for BRCA1 mutation carriers. The observed effect of oophorectomy was striking. © 2002 Wiley-Liss, Inc.